

A Jennifer Morton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7267582/publications.pdf>

Version: 2024-02-01

139
papers

8,461
citations

41323

49
h-index

49868

87
g-index

145
all docs

145
docs citations

145
times ranked

7578
citing authors

#	ARTICLE	IF	CITATIONS
1	Deep brain electrophysiology in freely moving sheep. <i>Current Biology</i> , 2022, 32, 763-774.e4.	1.8	4
2	Approaches to Sequence the HTT CAG Repeat Expansion and Quantify Repeat Length Variation. <i>Journal of Huntington's Disease</i> , 2021, 10, 53-74.	0.9	16
3	Abnormally abrupt transitions from sleep-to-wake in Huntington's disease sheep (<i>Ovis aries</i>) are revealed by automated analysis of sleep/wake transition dynamics. <i>PLoS ONE</i> , 2021, 16, e0251767.	1.1	11
4	Abnormal patterns of sleep and EEG power distribution during non-rapid eye movement sleep in the sheep model of Huntington's disease. <i>Neurobiology of Disease</i> , 2021, 155, 105367.	2.1	21
5	Increased plasma melatonin in presymptomatic Huntington disease sheep (<i>Ovis aries</i>): Compensatory neuroprotection in a neurodegenerative disease?. <i>Journal of Pineal Research</i> , 2020, 68, e12624.	3.4	18
6	Recommendations for measuring whisker movements and locomotion in mice with sensory, motor and cognitive deficits. <i>Journal of Neuroscience Methods</i> , 2020, 331, 108532.	1.3	9
7	Longitudinal Magnetic Resonance Spectroscopy and Diffusion Tensor Imaging in Sheep (<i>Ovis aries</i>) With Quinolinic Acid Lesions of the Striatum: Time-Dependent Recovery of N-Acetylaspartate and Fractional Anisotropy. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 1084-1092.	0.9	3
8	Characteristic patterns of EEG oscillations in sheep (<i>Ovis aries</i>) induced by ketamine may explain the psychotropic effects seen in humans. <i>Scientific Reports</i> , 2020, 10, 9440.	1.6	15
9	Expression and Localization of Kcne2 in the Vertebrate Retina. , 2020, 61, 33.		1
10	Wake-Promoting and EEG Spectral Effects of Modafinil After Acute or Chronic Administration in the R6/2 Mouse Model of Huntington's Disease. <i>Neurotherapeutics</i> , 2020, 17, 1075-1086.	2.1	8
11	Characterizing Sleep Spindles in Sheep. <i>ENeuro</i> , 2020, 7, ENEURO.0410-19.2020.	0.9	9
12	Antagonistic pleiotropy in mice carrying a CAG repeat expansion in the range causing Huntington's disease. <i>Scientific Reports</i> , 2019, 9, 37.	1.6	9
13	Abnormal Photic Entrainment to Phase-Delaying Stimuli in the R6/2 Mouse Model of Huntington's Disease, despite Retinal Responsiveness to Light. <i>ENeuro</i> , 2019, 6, ENEURO.0088-19.2019.	0.9	8
14	Neurological Examination of Sheep (<i>Ovis aries</i>) with Unilateral and Bilateral Quinolinic Acid Lesions of the Striatum Assessed by Magnetic Resonance Imaging. <i>Journal of Neurology and Experimental Neuroscience</i> , 2019, 05, .	0.2	3
15	Single-Cell RNA-Seq of Mouse Dopaminergic Neurons Informs Candidate Gene Selection for Sporadic Parkinson Disease. <i>American Journal of Human Genetics</i> , 2018, 102, 427-446.	2.6	102
16	Early Neurodegeneration in R6/2 Mice Carrying the Huntington's Disease Mutation with a Super-Expanded CAG Repeat, Despite Normal Lifespan. <i>Journal of Huntington's Disease</i> , 2018, 7, 61-76.	0.9	2
17	Chronic paroxetine treatment prevents disruption of methamphetamine-sensitive circadian oscillator in a transgenic mouse model of Huntington's disease. <i>Neuropharmacology</i> , 2018, 131, 337-350.	2.0	8
18	Characterisation of progressive motor deficits in whisker movements in R6/2, Q175 and Hdh knock-in mouse models of Huntington's disease. <i>Journal of Neuroscience Methods</i> , 2018, 300, 103-111.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease. <i>Human Gene Therapy</i> , 2018, 29, 663-673.	1.4	74
20	Indices of comparative cognition: assessing animal models of human brain function. <i>Experimental Brain Research</i> , 2018, 236, 3379-3390.	0.7	12
21	mHTT Seeding Activity: A Marker of Disease Progression and Neurotoxicity in Models of Huntington's Disease. <i>Molecular Cell</i> , 2018, 71, 675-688.e6.	4.5	50
22	XJB-5-131-mediated improvement in physiology and behaviour of the R6/2 mouse model of Huntington's disease is age- and sex- dependent. <i>PLoS ONE</i> , 2018, 13, e0194580.	1.1	20
23	Visual attention and cognitive performance in sheep. <i>Applied Animal Behaviour Science</i> , 2018, 206, 52-58.	0.8	8
24	Large-Brained Animal Models of Huntington's Disease: Sheep. <i>Methods in Molecular Biology</i> , 2018, 1780, 221-239.	0.4	18
25	Potential molecular consequences of transgene integration: The R6/2 mouse example. <i>Scientific Reports</i> , 2017, 7, 41120.	1.6	14
26	Metabolic profiling of presymptomatic Huntington's disease sheep reveals novel biomarkers. <i>Scientific Reports</i> , 2017, 7, 43030.	1.6	78
27	A stop-signal task for sheep: introduction and validation of a direct measure for the stop-signal reaction time. <i>Animal Cognition</i> , 2017, 20, 615-626.	0.9	15
28	Techniques for chronic monitoring of brain activity in freely moving sheep using wireless EEG recording. <i>Journal of Neuroscience Methods</i> , 2017, 279, 87-100.	1.3	26
29	Prolonged day length exposure improves circadian deficits and survival in a transgenic mouse model of Huntington's disease. <i>Neurobiology of Sleep and Circadian Rhythms</i> , 2017, 2, 27-38.	1.4	15
30	Chronic Paroxetine Treatment Prevents the Emergence of Abnormal Electroencephalogram Oscillations in Huntington's Disease Mice. <i>Neurotherapeutics</i> , 2017, 14, 1120-1133.	2.1	10
31	Sheep recognize familiar and unfamiliar human faces from two-dimensional images. <i>Royal Society Open Science</i> , 2017, 4, 171228.	1.1	56
32	Attenuated pupillary light responses and downregulation of opsin expression parallel decline in circadian disruption in two different mouse models of Huntington's disease. <i>Human Molecular Genetics</i> , 2016, 25, ddd359.	1.4	14
33	Impaired Nitric Oxide Mediated Vasodilation In The Peripheral Circulation In The R6/2 Mouse Model Of Huntington's Disease. <i>Scientific Reports</i> , 2016, 6, 25979.	1.6	6
34	Delayed Onset and Reduced Cognitive Deficits through Pre-Conditioning with 3-Nitropropionic Acid is Dependent on Sex and CAG Repeat Length in the R6/2 Mouse Model of Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2016, 5, 19-32.	0.9	13
35	Similar Progression of Morphological and Metabolic Phenotype in R6/2 Mice with Different CAG Repeats Revealed by In Vivo Magnetic Resonance Imaging and Spectroscopy. <i>Journal of Huntington's Disease</i> , 2016, 5, 271-283.	0.9	1
36	Automated detection and characterisation of rumination in sheep using in vivo electrophysiology. <i>Physiology and Behavior</i> , 2016, 163, 258-266.	1.0	8

#	ARTICLE	IF	CITATIONS
37	Progressive gene dose-dependent disruption of the methamphetamine-sensitive circadian oscillator-driven rhythms in a knock-in mouse model of Huntington's disease. <i>Experimental Neurology</i> , 2016, 286, 69-82.	2.0	8
38	An EEG Investigation of Sleep Homeostasis in Healthy and CLN5 Batten Disease Affected Sheep. <i>Journal of Neuroscience</i> , 2016, 36, 8238-8249.	1.7	27
39	A single dose of hypnotic corrects sleep and EEG abnormalities in symptomatic Huntington's disease mice. <i>Neuropharmacology</i> , 2016, 105, 298-307.	2.0	18
40	Allelic series of Huntington's disease knock-in mice reveals expression dis-correlates. <i>Human Molecular Genetics</i> , 2016, 25, 1619-1636.	1.4	15
41	A comparison of discrimination learning in touchscreen and 2-choice swim tank using an allelic series of Huntington's disease mice. <i>Journal of Neuroscience Methods</i> , 2016, 265, 56-71.	1.3	5
42	The Cambridge MRI database for animal models of Huntington disease. <i>NeuroImage</i> , 2016, 124, 1260-1262.	2.1	4
43	A mobile, high-throughput semi-automated system for testing cognition in large non-primate animal models of Huntington disease. <i>Journal of Neuroscience Methods</i> , 2016, 265, 25-33.	1.3	27
44	Social Behaviour is Impaired in the R6/2 Mouse Model of Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2015, 4, 61-73.	0.9	12
45	Rapid and Progressive Regional Brain Atrophy in CLN6 Batten Disease Affected Sheep Measured with Longitudinal Magnetic Resonance Imaging. <i>PLoS ONE</i> , 2015, 10, e0132331.	1.1	20
46	A Significance Test for Inferring Affiliation Networks from Spatio-Temporal Data. <i>PLoS ONE</i> , 2015, 10, e0132417.	1.1	2
47	Progression of behavioural despair in R6/2 and Hdh knock-in mouse models recapitulates depression in Huntington's disease. <i>Behavioural Brain Research</i> , 2015, 291, 140-146.	1.2	19
48	Age-, tissue- and length-dependent bidirectional somatic CAGâ€¦CTG repeat instability in an allelic series of R6/2 Huntington disease mice. <i>Neurobiology of Disease</i> , 2015, 76, 98-111.	2.1	33
49	Translational neurophysiology in sheep: measuring sleep and neurological dysfunction in CLN5 Batten disease affected sheep. <i>Brain</i> , 2015, 138, 862-874.	3.7	39
50	Technical note: Validation of an automatic recording system to assess behavioural activity level in sheep (<i>Ovis aries</i>). <i>Small Ruminant Research</i> , 2015, 127, 92-96.	0.6	25
51	Right Ventricular Dysfunction in the R6/2 Transgenic Mouse Model of Huntington's Disease is Unmasked by Dobutamine. <i>Journal of Huntington's Disease</i> , 2014, 3, 25-32.	0.9	17
52	Solving the shepherding problem: heuristics for herding autonomous, interacting agents. <i>Journal of the Royal Society Interface</i> , 2014, 11, 20140719.	1.5	140
53	Behavioral therapy reverses circadian deficits in a transgenic mouse model of Huntington's disease. <i>Neurobiology of Disease</i> , 2014, 63, 85-91.	2.1	41
54	Expression levels of DNA replication and repair genes predict regional somatic repeat instability in the brain but are not altered by polyglutamine disease protein expression or age. <i>Human Molecular Genetics</i> , 2014, 23, 1606-1618.	1.4	47

#	ARTICLE	IF	CITATIONS
55	Beneficial effects of environmental enrichment and food entrainment in the R6/2 mouse model of Huntington's disease. <i>Brain and Behavior</i> , 2014, 4, 675-686.	1.0	36
56	Early and progressive circadian abnormalities in Huntington's disease sheep are unmasked by social environment. <i>Human Molecular Genetics</i> , 2014, 23, 3375-3383.	1.4	78
57	Circadian and sleep disorder in Huntington's disease. <i>Experimental Neurology</i> , 2013, 243, 34-44.	2.0	115
58	Choosing an animal model for the study of Huntington's disease. <i>Nature Reviews Neuroscience</i> , 2013, 14, 708-721.	4.9	287
59	Restriction endonuclease TseI cleaves A:A and T:T mismatches in CAG and CTG repeats. <i>Nucleic Acids Research</i> , 2013, 41, 4999-5009.	6.5	10
60	Voxel-based morphometry with templates and validation in a mouse model of Huntington's disease. <i>Magnetic Resonance Imaging</i> , 2013, 31, 1522-1531.	1.0	62
61	Progressive sleep and electroencephalogram changes in mice carrying the Huntington's disease mutation. <i>Brain</i> , 2013, 136, 2147-2158.	3.7	63
62	Large Genetic Animal Models of Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2013, 2, 3-19.	0.9	92
63	Further Molecular Characterisation of the OVT73 Transgenic Sheep Model of Huntington's Disease Identifies Cortical Aggregates. <i>Journal of Huntington's Disease</i> , 2013, 2, 279-295.	0.9	47
64	Adaptation to Experimental Jet-Lag in R6/2 Mice despite Circadian Dysrhythmia. <i>PLoS ONE</i> , 2013, 8, e55036.	1.1	10
65	Combining Comparative Proteomics and Molecular Genetics Uncovers Regulators of Synaptic and Axonal Stability and Degeneration In Vivo. <i>PLoS Genetics</i> , 2012, 8, e1002936.	1.5	54
66	Direct Visualisation of Abnormal Dendritic Spine Morphology in the Hippocampus of the R6/2 Transgenic Mouse Model of Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2012, 1, 267-273.	0.9	15
67	Data-loggers carried on a harness do not adversely affect sheep locomotion. <i>Research in Veterinary Science</i> , 2012, 93, 549-552.	0.9	12
68	Selfish-herd behaviour of sheep under threat. <i>Current Biology</i> , 2012, 22, R561-R562.	1.8	114
69	Tensor-Based Morphometry and Stereology Reveal Brain Pathology in the Complexin1 Knockout Mouse. <i>PLoS ONE</i> , 2012, 7, e32636.	1.1	21
70	Temporal Separation of Aggregation and Ubiquitination during Early Inclusion Formation in Transgenic Mice Carrying the Huntington's Disease Mutation. <i>PLoS ONE</i> , 2012, 7, e41450.	1.1	22
71	Direct Evidence of Progressive Cardiac Dysfunction in a Transgenic Mouse Model of Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2012, 1, 57-64.	0.9	31
72	The methamphetamine-sensitive circadian oscillator is dysfunctional in a transgenic mouse model of Huntington's disease. <i>Neurobiology of Disease</i> , 2012, 45, 145-155.	2.1	28

#	ARTICLE	IF	CITATIONS
73	Huntington's Disease Mouse Models Online: High-Resolution MRI Images with Stereotaxic Templates for Computational Neuroanatomy. PLoS ONE, 2012, 7, e53361.	1.1	9
74	Executive Decision-Making in the Domestic Sheep. PLoS ONE, 2011, 6, e15752.	1.1	59
75	Unusual Structures Are Present in DNA Fragments Containing Super-Long Huntingtin CAG Repeats. PLoS ONE, 2011, 6, e17119.	1.1	19
76	Brain training improves cognitive performance and survival in a transgenic mouse model of Huntington's disease. Neurobiology of Disease, 2011, 42, 427-437.	2.1	70
77	Paradoxical function of orexin/hypocretin circuits in a mouse model of Huntington's disease. Neurobiology of Disease, 2011, 42, 438-445.	2.1	45
78	Determining association networks in social animals: choosing spatial-temporal criteria and sampling rates. Behavioral Ecology and Sociobiology, 2011, 65, 1659-1668.	0.6	54
79	Asymptomatic Sleep Abnormalities Are a Common Early Feature in Patients with Huntington's Disease. Current Neurology and Neuroscience Reports, 2011, 11, 211-217.	2.0	93
80	Synaptic Dysfunction in Huntington's Disease. , 2011, , 233-255.		0
81	Clorgyline-mediated reversal of neurological deficits in a Complexin 2 knockout mouse. Human Molecular Genetics, 2010, 19, 3402-3412.	1.4	17
82	Disruption of Peripheral Circadian Timekeeping in a Mouse Model of Huntington's Disease and Its Restoration by Temporally Scheduled Feeding. Journal of Neuroscience, 2010, 30, 10199-10204.	1.7	125
83	Identifying sleep disturbances in Huntington's disease using a simple disease-focused questionnaire. PLOS Currents, 2010, 2, RRN1189.	1.4	36
84	Responses to Environmental Enrichment Differ with Sex and Genotype in a Transgenic Mouse Model of Huntington's Disease. PLoS ONE, 2010, 5, e9077.	1.1	73
85	Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiology of Disease, 2009, 33, 331-341.	2.1	114
86	Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiology of Disease, 2009, 35, 319-336.	2.1	281
87	Management of sleep/wake cycles improves cognitive function in a transgenic mouse model of Huntington's disease. Brain Research, 2009, 1279, 90-98.	1.1	81
88	The detection and measurement of locomotor deficits in a transgenic mouse model of Huntington's disease are task- and protocol-dependent: Influence of non-motor factors on locomotor function. Brain Research Bulletin, 2009, 78, 347-355.	1.4	56
89	Progressive imbalance in the interaction between spatial and procedural memory systems in the R6/2 mouse model of Huntington's disease. Neurobiology of Learning and Memory, 2009, 92, 417-428.	1.0	44
90	Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease. Journal of Neurochemistry, 2008, 76, 166-172.	2.1	85

#	ARTICLE	IF	CITATIONS
91	Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation. <i>Brain Research</i> , 2008, 1188, 61-68.	1.1	32
92	Increased metabolism in the R6/2 mouse model of Huntington's disease. <i>Neurobiology of Disease</i> , 2008, 29, 41-51.	2.1	114
93	Rigidity in social and emotional memory in the R6/2 mouse model of Huntington's disease. <i>Neurobiology of Learning and Memory</i> , 2008, 89, 533-544.	1.0	36
94	Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death. <i>Brain Research Bulletin</i> , 2008, 75, 146-157.	1.4	39
95	Increased thirst and drinking in Huntington's disease and the R6/2 mouse. <i>Brain Research Bulletin</i> , 2008, 76, 70-79.	1.4	82
96	The metabolic profile of early Huntington's disease- a combined human and transgenic mouse study. <i>Experimental Neurology</i> , 2008, 210, 691-698.	2.0	99
97	The touchscreen cognitive testing method for rodents: How to get the best out of your rat. <i>Learning and Memory</i> , 2008, 15, 516-523.	0.5	228
98	Identity, developmental restriction and reactivity of extralaminar cells capping mammalian neuromuscular junctions. <i>Journal of Cell Science</i> , 2008, 121, 3901-3911.	1.2	63
99	Pharmacological Imposition of Sleep Slows Cognitive Decline and Reverses Dysregulation of Circadian Gene Expression in a Transgenic Mouse Model of Huntington's Disease. <i>Journal of Neuroscience</i> , 2007, 27, 7869-7878.	1.7	185
100	Complexin 1 knockout mice exhibit marked deficits in social behaviours but appear to be cognitively normal. <i>Human Molecular Genetics</i> , 2007, 16, 2288-2305.	1.4	49
101	Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD. <i>Brain Research Bulletin</i> , 2007, 72, 108-120.	1.4	19
102	Olfactory abnormalities in Huntington's disease: Decreased plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory discrimination in patients. <i>Brain Research</i> , 2007, 1151, 219-226.	1.1	62
103	Systemic administration of Congo red does not improve motor or cognitive function in R6/2 mice. <i>Neurobiology of Disease</i> , 2007, 25, 342-353.	2.1	28
104	Early motor development is abnormal in complexin 1 knockout mice. <i>Neurobiology of Disease</i> , 2007, 25, 483-495.	2.1	32
105	Differential morphology and composition of inclusions in the R6/2 mouse and PC12 cell models of Huntington's disease. <i>Histochemistry and Cell Biology</i> , 2007, 127, 473-484.	0.8	18
106	Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation. <i>Brain Research Bulletin</i> , 2006, 69, 669-679.	1.4	26
107	Limbic neurogenesis/plasticity in the R6/2 mouse model of Huntington's disease. <i>NeuroReport</i> , 2006, 17, 1623-1627.	0.6	18
108	Measuring cognitive deficits in disabled mice using an automated interactive touchscreen system. <i>Nature Methods</i> , 2006, 3, 767-767.	9.0	78

#	ARTICLE	IF	CITATIONS
109	A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease. <i>European Journal of Neuroscience</i> , 2005, 21, 855-870.	1.2	71
110	A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse. <i>European Journal of Neuroscience</i> , 2005, 22, 1701-1712.	1.2	52
111	Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents. <i>Experimental Brain Research</i> , 2005, 166, 220-229.	0.7	54
112	Profound ataxia in complexin I knockout mice masks a complex phenotype that includes exploratory and habituation deficits. <i>Human Molecular Genetics</i> , 2005, 14, 2369-2385.	1.4	71
113	Disintegration of the Sleep-Wake Cycle and Circadian Timing in Huntington's Disease. <i>Journal of Neuroscience</i> , 2005, 25, 157-163.	1.7	361
114	Abnormalities of Neurogenesis in the R6/2 Mouse Model of Huntington's Disease Are Attributable to the In Vivo Microenvironment. <i>Journal of Neuroscience</i> , 2005, 25, 11564-11576.	1.7	116
115	Ecstasy: pharmacology and neurotoxicity. <i>Current Opinion in Pharmacology</i> , 2005, 5, 79-86.	1.7	116
116	Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation. <i>European Journal of Neuroscience</i> , 2004, 20, 3092-3114.	1.2	151
117	Differential messenger RNA expression of complexins in mouse brain. <i>Brain Research Bulletin</i> , 2004, 63, 33-44.	1.4	29
118	Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's Disease mutation. <i>Brain Research Bulletin</i> , 2004, 63, 45-55.	1.4	39
119	RAGE is expressed in pyramidal cells of the hippocampus following moderate hypoxic-ischemic brain injury in rats. <i>Brain Research</i> , 2003, 966, 167-174.	1.1	49
120	Microglia density decreases with age in a mouse model of Huntington's disease. <i>Glia</i> , 2003, 43, 274-280.	2.5	57
121	Complexin II is essential for normal neurological function in mice. <i>Human Molecular Genetics</i> , 2003, 12, 2431-2448.	1.4	101
122	Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation. <i>Brain Research Bulletin</i> , 2003, 61, 375-383.	1.4	73
123	Expression of Mutant Huntingtin Blocks Exocytosis in PC12 Cells by Depletion of Complexin II. <i>Journal of Biological Chemistry</i> , 2003, 278, 30849-30853.	1.6	48
124	Mice Transgenic for the Huntington's Disease Mutation Are Resistant to Chronic 3-Nitropropionic Acid-Induced Striatal Toxicity. <i>Journal of Neurochemistry</i> , 2002, 75, 2163-2171.	2.1	50
125	The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. <i>Journal of Neurochemistry</i> , 2002, 81, 46-59.	2.1	98
126	Abnormalities in the synaptic vesicle fusion machinery in Huntington's disease. <i>Brain Research Bulletin</i> , 2001, 56, 111-117.	1.4	127

#	ARTICLE	IF	CITATIONS
127	Methamphetamine toxicity in mice is potentiated by exposure to loud music. <i>NeuroReport</i> , 2001, 12, 3277-3281.	0.6	34
128	Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. <i>Movement Disorders</i> , 2000, 15, 925-937.	2.2	96
129	Abnormal Synaptic Plasticity and Impaired Spatial Cognition in Mice Transgenic for Exon 1 of the Human Huntington's Disease Mutation. <i>Journal of Neuroscience</i> , 2000, 20, 5115-5123.	1.7	366
130	Mice transgenic for the human Huntington's disease mutation have reduced sensitivity to kainic acid toxicity. <i>Brain Research Bulletin</i> , 2000, 52, 51-59.	1.4	61
131	Characterization of Progressive Motor Deficits in Mice Transgenic for the Human Huntington's Disease Mutation. <i>Journal of Neuroscience</i> , 1999, 19, 3248-3257.	1.7	864
132	Selective Discrimination Learning Impairments in Mice Expressing the Human Huntington's Disease Mutation. <i>Journal of Neuroscience</i> , 1999, 19, 10428-10437.	1.7	355
133	Magic Molecules, How Drugs Work Susan Aldridge Cambridge University Press, Cambridge, 1998 (269) Tj ETQq1 1 0.784314,rgBT /Over 0,4	0.4	0
134	Dopamine Modulates the Susceptibility of Striatal Neurons to 3-Nitropropionic Acid in the Rat Model of Huntington's Disease. <i>Journal of Neuroscience</i> , 1998, 18, 10116-10127.	1.7	114
135	Cortical induction of c-fos by intrastriatal endothelin-1 is mediated via NMDA receptors. <i>NeuroReport</i> , 1996, 8, 211-216.	0.6	6
136	Cerebellar neurons and glia respond differentially to endothelins and sarafotoxin S6b. <i>Brain Research</i> , 1992, 581, 299-306.	1.1	35
137	Accelerated Differentiation in Response to Retinoic Acid After Retrovirally Mediated Gene Transfer of GAP-43 into Mouse Neuroblastoma Cells. <i>European Journal of Neuroscience</i> , 1992, 4, 910-916.	1.2	36
138	Binding sites for ¹²⁵ I ET-1, ET-2, ET-3 and vasoactive intestinal contractor are present in adult rat brain and neurone-enriched primary cultures of embryonic brain cells. <i>Brain Research</i> , 1991, 554, 278-285.	1.1	40
139	Expression of calbindin D-28K-like immunoreactivity in human SK-N-SH and SH-SY-5Y neuroblastoma cells. <i>Brain Research</i> , 1990, 533, 161-164.	1.1	10